Pharmacoeconomic analysis of clopidogrel in secondary prevention of coronary artery disease.

@article{Cheng2007PharmacoeconomicAO,
  title={Pharmacoeconomic analysis of clopidogrel in secondary prevention of coronary artery disease.},
  author={Judy Cheng},
  journal={Journal of managed care pharmacy : JMCP},
  year={2007},
  volume={13 4},
  pages={
          326-36
        }
}
BACKGROUND When used as an alternative to or in addition to aspirin, clopidogrel has been demonstrated by some but not all randomized controlled trials to be effective in secondary prevention of cardiovascular (CV) events in patients with (1) coronary artery disease (CAD), (2) acute coronary syndrome (ACS), and (3) coronary stent placement. However, a drawback to clopidogrel therapy is the cost to patients and the health care system. Clinical studies have also demonstrated that when clopidogrel… CONTINUE READING
BETA